Andres
Iñiguez Romo
Jagiellonian University
Cracovia, PoloniaPublicacións en colaboración con investigadores/as de Jagiellonian University (10)
2022
-
Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: Final results of the SYNTAX II study
European Heart Journal, Vol. 43, Núm. 13, pp. 1307-1316
2020
-
Bioresorbable scaffolds versus everolimus-eluting metallic stents: Five-year clinical outcomes of the randomised ABSORB II trial
EuroIntervention, Vol. 16, Núm. 11, pp. E938-E941
-
Endothelial shear stress and vascular remodeling in bioresorbable scaffold and metallic stent
Atherosclerosis, Vol. 312, pp. 79-89
2019
-
Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease: Twoyear follow-up of the SYNTAX II study
EuroIntervention, Vol. 15, Núm. 3, pp. E244-A252
2018
2017
-
Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study
European Heart Journal, Vol. 38, Núm. 42, pp. 3124-3134
-
Comparison of everolimus-eluting bioresorbable scaffolds with everolimuseluting metallic stents for treatment of coronary artery stenosis: Three-year follow-up of the ABSORB II randomized trial
Bioresorbable Scaffolds: From Basic Concept to Clinical Applications (CRC Press), pp. 224-237
2016
-
A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy
Cardiovascular Revascularization Medicine, Vol. 17, Núm. 6, pp. 355-361
-
Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial
The Lancet, Vol. 388, Núm. 10059, pp. 2479-2491
2015
-
A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial
The Lancet, Vol. 385, Núm. 9962, pp. 43-54